External Validation of the FREEDOM Score for Individualized Decision Making Between CABG and PCI.

Abstract

BACKGROUND:

Although randomized trials have established that coronary artery bypass grafting (CABG) is, on average, the most effective revascularization strategy compared with percutaneous coronary intervention (PCI) in patients with diabetes and multivessel disease (MVD), individual patients differ in many characteristics that can affect the benefits and harms of treatment. The FREEDOM (Future Revascularization Evaluation in Patients with Diabetes Mellitus) score was developed to predict different outcomes with CABG vs PCI on the basis of 8 patient characteristics and the smoking-treatment interaction.

OBJECTIVES:

This study aimed to assess the ability of the 5-year major adverse cardiovascular event (MACE) model to predict treatment benefit of CABG vs PCI in the SYNTAX (Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery) and BEST (Bypass Surgery and Everolimus-Eluting Stent Implantation in the Treatment of Patients with Multivessel Coronary Artery Disease) trials.

METHODS:

This study identified 702 patients with diabetes and MVD to mirror the FREEDOM participants. Discrimination was assessed by C-index, and calibration was assessed by calibration plots in the PCI and CABG arms, respectively. The ability of the FREEDOM score to predict treatment benefit of CABG vs PCI was assessed.

RESULTS:

Overall, CABG was associated with a lower rate of 5-year MACE compared with PCI (12.4% vs 20.3%; log-rank P = 0.021) irrespective of a history of smoking (Pinteraction = 0.975). Both discrimination and calibration were helpful in the PCI arm (C-index: 0.69; slope: 0.96, intercept: -0.24), but moderate in the CABG arm (C-index: 0.61; slope: 0.61; intercept: -0.53). The FREEDOM score showed some heterogeneity of treatment benefit.

CONCLUSIONS:

The FREEDOM score could identify some heterogeneity of treatment benefit of CABG vs PCI for 5-year MACE. Until further prospective validations are performed, these results should be taken into consideration when using the FREEDOM score in patients with diabetes and MVD. (Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery [SYNTAX]; NCT00114972) (Bypass Surgery and Everolimus-Eluting Stent Implantation in the Treatment of Patients with Multivessel Coronary Artery Disease [BEST]; NCT00997828) (Future Revascularization Evaluation in Patients with Diabetes Mellitus [FREEDOM]; NCT00086450).

• Authors: Kuniaki Takahashi, Patrick W Serruys, Valentin Fuster, Michael E Farkouh, John A Spertus, David J Cohen, Seung-Jung Park, Duk-Woo Park, Jung-Min Ahn, Yoshinobu Onuma, David M Kent, Ewout W Steyerberg, David van Klaveren, SYNTAX, BEST, and FREEDOM Trial investigators
• Journal: Journal of the American College of Cardiology (J Am Coll Cardiol) Vol. 79 Issue 15 Pg. 1458-1473 (04 19 2022) ISSN: 1558-3597 [Electronic] United States
• PMID: 35422242 (Publication Type: Clinical Study, Journal Article)
• Copyright: Copyright © 2022 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Chemical References

• Everolimus

Topics

• Coronary Artery Bypass (adverse effects)
• Coronary Artery Disease (epidemiology, surgery)
• Decision Support Systems, Clinical
• Diabetes Mellitus (epidemiology)
• Drug-Eluting Stents
• Everolimus
• Humans
• Percutaneous Coronary Intervention (adverse effects)
• Reproducibility of Results
• Treatment Outcome